TRT, Diabetes, and Insulin Resistance — Does Testosterone Affect Blood Sugar?

A man with type 2 diabetes or marked insulin resistance who's also found to have low testosterone isn't a rarity in clinical practice — it's more the rule. Cross-sectional studies consistently show that testosterone deficiency in men with type 2 diabetes occurs several times more often than in the general population, with the affected proportion ranging, depending on the diagnostic criteria used, from a quarter to more than half of those studied. This isn't a coincidence or an age effect — it's a documented, bidirectional relationship worth understanding before the question of whether testosterone replacement therapy (TRT) can help control blood sugar comes up.

This article isn't a general introduction to insulin resistance or to TRT itself — we cover those topics separately. We focus exclusively on where they intersect: what's actually known about testosterone's effect on carbohydrate metabolism, what hard data come from interventional trials, and — just as important — what TRT doesn't do in this context.

It's worth setting the right scale of expectations right away. The question "does testosterone affect blood sugar" has two separate answers that are easy to mix up. The first concerns epidemiology — does low testosterone raise the risk of developing diabetes in the male population. The second concerns therapy — does giving testosterone to a man who already has diabetes improve its control. The answer to the first question is fairly clear-cut today. The answer to the second is more nuanced: the effect exists, is replicated across several independent studies, but is moderate in size and applies to a narrowly defined group of patients.

The epidemiological relationship between low testosterone and type 2 diabetes is one of the better-confirmed ones in all of metabolic endocrinology. Meta-analyses of cohort studies consistently show that men with higher testosterone levels have significantly lower risk of developing type 2 diabetes in subsequent years of follow-up — a relationship that holds even after statistically accounting for age and body mass index, though of course it doesn't fully eliminate the problem of reverse causation (obesity and insulin resistance themselves lower testosterone, which complicates a clear-cut interpretation of the direction of the relationship).

It's worth stressing that this is observational data — it shows a strong association but doesn't by itself prove that low testosterone directly causes diabetes. Mechanistically, though, the relationship is plausible and multidirectional, which we cover in the next section.

A similar picture emerges from cross-sectional studies conducted directly among men who already have type 2 diabetes — testosterone deficiency is markedly more common among them than in peers without diabetes, regardless of whether the diagnosis was recent or the disease has lasted for years. In other words, low testosterone accompanies type 2 diabetes not just at the stage of its development, but throughout its entire course — making this topic relevant not just to prevention, but to the everyday management of already-diagnosed patients.

Testosterone affects several metabolic processes relevant to insulin sensitivity at the same time, which makes the relationship biologically plausible rather than a purely statistical artifact.

This vicious circle has an important practical consequence: in some men with obesity and diabetes, weight loss alone — with no hormone therapy at all — can significantly raise endogenous testosterone, because it removes one link in that cycle (excess fat tissue and the aromatization tied to it). For that reason, in a man with obesity, diabetes, and low testosterone, the first, cheapest, side-effect-free step always remains weight loss and lifestyle improvement — only if that isn't enough and hypogonadism persists does considering TRT as a supplement become sensible.

This is the question answered not by observational studies but by randomized clinical trials — and here the evidence is, compared to many other areas of TRT application, relatively solid. The most important of these remains TIMES2 (Testosterone therapy In hypogonadal Men with Either type 2 diabetes or metabolic Syndrome) — a 12-month, multicenter, randomized, double-blind, placebo-controlled trial conducted across several European countries in 220 hypogonadal men with type 2 diabetes and/or metabolic syndrome.

TIMES2's result matters for two reasons. First, it shows an effect on a hard, recognized indicator of insulin sensitivity (HOMA-IR), not just on subjective symptoms. Second, the scale of improvement — around 15% reduction in insulin resistance — is compared in the literature to the effect of metformin, the first-line drug for type 2 diabetes. That doesn't mean TRT "works like metformin" in a clinical sense (the mechanism, safety profile, and scope of indications are entirely different), but it shows the metabolic effect isn't negligible.

The HbA1c result requires an honest caveat: a 0.4-percentage-point drop is clinically noticeable, but in the TIMES2 trial itself it didn't reach full statistical significance for the whole sample, which was later also discussed and commented on in the specialist literature. Other, smaller studies and meta-analyses of TRT in men with diabetes and hypogonadism generally confirm the direction of the effect — improved insulin sensitivity and a modest but repeatable improvement in glycemia — with inconsistent findings on its exact magnitude and durability.

Endocrine Society guidelines on testosterone therapy for hypogonadism don't define diabetes or insulin resistance as a separate, standalone indication for TRT. They recommend diagnosing and treating hypogonadism on the same terms as in other men — a confirmed low testosterone level across at least two morning measurements, combined with clinical symptoms. Coexisting type 2 diabetes doesn't lower the diagnostic threshold or serve as a standalone justification for therapy, but it can be an additional argument for testosterone screening in men with diabetes who develop typical symptoms suggesting a deficiency.

The real clinical scenario where this knowledge matters looks like this: a man diagnosed with type 2 diabetes or marked insulin resistance, whose two morning tests confirm low testosterone, and who has present symptoms of hypogonadism (reduced libido, erectile dysfunction, loss of muscle mass, chronic fatigue). In this situation, TRT — managed by an endocrinologist, alongside continued standard diabetes treatment — can bring a double benefit: improved hypogonadism symptoms and additional, modest support for metabolic control.

A separate, legitimate concern with TRT in men with diabetes is cardiovascular safety — this group already has elevated risk of heart attack and stroke simply from diabetes, so the question of whether testosterone therapy adds to that risk is entirely reasonable. The largest study to date assessing this question, TRAVERSE, enrolled more than 5,200 hypogonadal men with existing or high cardiovascular risk (including a significant proportion with diabetes) and found no increased risk of major cardiovascular events with TRT versus placebo. That's important, reassuring data, though the study wasn't specifically designed for a diabetic population, so individual risk assessment by the prescribing doctor remains necessary.

It has to be honestly acknowledged that the evidence, though more solid than in many other "peripheral" TRT applications, still has limitations. TIMES2 and similar studies are relatively small by the standards of registration trials for diabetes drugs, follow-up rarely exceeds 12–24 months, and hard patient-relevant endpoints — such as reducing microvascular and macrovascular diabetes complications over the long term — haven't yet been directly studied in the context of TRT. In other words: we know fairly well that TRT improves indirect metabolic markers (HOMA-IR, to a lesser extent HbA1c) in hypogonadal men with diabetes, but we don't have data showing this translates into fewer heart attacks, strokes, or kidney complications over a decade.

A further interpretive difficulty is that the available studies differ in the testosterone delivery form used (transdermal gel, intramuscular injections at varying frequency, implants), the target hormone concentration, and the criteria for diagnosing hypogonadism — not always identical to those used in everyday clinical practice in Poland. For that reason, figures like "15% reduction in HOMA-IR" are best treated as an indicative, averaged signal of the direction and scale of the effect, not a guaranteed result for a specific patient.

If you're a man with type 2 diabetes or marked insulin resistance and suspect you have low testosterone, it's worth checking — not to replace diabetes treatment with testosterone, but because hypogonadism itself is a condition worth treating, and any additional improvement in insulin sensitivity is a bonus, not plan A. This conversation about TRT is best held jointly with a diabetes specialist and an endocrinologist, so that monitoring and treatment decisions account for the full metabolic picture, not just the hormone level alone.